Compounds > bottromycin a(2)
Page last updated: 2024-11-13

bottromycin a(2)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bottromycin A(2): from streptomyces; specific inhibitor to protein sythesinin the in vivo & in vitro bacterial systems; structure; see also record for bottromycin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID25215756
CHEMBL ID1256112
SCHEMBL ID13383277
MeSH IDM0059116

Synonyms (7)

Synonym
bottromycin a(2)
15005-62-6
bottromycin a2
CHEMBL1256112
SCHEMBL13383277
DTXSID701028185
AKOS040755423
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID517669Antimicrobial activity against Enterococcus faecium NCTC 12201 by standard serial-dilution technique2010Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20
Bottromycin derivatives: efficient chemical modifications of the ester moiety and evaluation of anti-MRSA and anti-VRE activities.
AID517668Antimicrobial activity against methicillin-resistant Staphylococcus aureus 92-1191 by standard serial-dilution technique2010Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20
Bottromycin derivatives: efficient chemical modifications of the ester moiety and evaluation of anti-MRSA and anti-VRE activities.
AID517670Antimicrobial activity against Enterococcus faecium NCTC 12203 by standard serial-dilution technique2010Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20
Bottromycin derivatives: efficient chemical modifications of the ester moiety and evaluation of anti-MRSA and anti-VRE activities.
AID517666Antimicrobial activity against Staphylococcus aureus Smith by standard serial-dilution technique2010Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20
Bottromycin derivatives: efficient chemical modifications of the ester moiety and evaluation of anti-MRSA and anti-VRE activities.
AID517667Antimicrobial activity against methicillin-resistant Staphylococcus aureus HH1 by standard serial-dilution technique2010Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20
Bottromycin derivatives: efficient chemical modifications of the ester moiety and evaluation of anti-MRSA and anti-VRE activities.
AID517671Antimicrobial activity against methicillin-resistant Staphylococcus aureus assessed as rate of residual activity2010Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20
Bottromycin derivatives: efficient chemical modifications of the ester moiety and evaluation of anti-MRSA and anti-VRE activities.
AID517665Antimicrobial activity against Staphylococcus aureus FDA209P by standard serial-dilution technique2010Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20
Bottromycin derivatives: efficient chemical modifications of the ester moiety and evaluation of anti-MRSA and anti-VRE activities.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (33.33)18.7374
1990's1 (11.11)18.2507
2000's1 (11.11)29.6817
2010's4 (44.44)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.37 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		2.0510glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
puromycin
[no description available]		2.3620puromycinsantiinfective agent;
antimicrobial agent;
antineoplastic agent;
EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor;
EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor;
nucleoside antibiotic;
protein synthesis inhibitor
linezolid
[no description available]		2.0510acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Bacterial Infections, Gram-Positive
[description not available]		02.0510
Gram-Positive Bacterial Infections
Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.		02.0510